Glide Pharma announces third new collaboration partner
Oxford-based specialty pharma company, Glide Pharma, has signed agreements with two more partners to evaluate its solid dose injector technology, the Glide SDI. This follows a deal in February with another leading pharmaceutical company for the delivery of one of its branded peptide products
Oxford-based specialty pharma company, Glide Pharma, has signed agreements with two more partners to evaluate its solid dose injector technology, the Glide SDI. This follows a deal in February with another leading pharmaceutical company for the delivery of one of its branded peptide products
The latest studies involve biologics and include a major vaccine company and a listed US biotech company for a home-delivered product.
Responding to the latest developments Glide Pharma's CEO, Dr Charles Potter, said, We believe that the Glide SDI is set to make major improvements in the injection of biologics, in a market which is predicted to grow to over $50bn by 2012..
The company is also working with the UK's National Institute of Biological Standards and Control (NISBC) that has been conducting studies on vaccine administration using formulations developed by Glide Pharma.
With an increasing number of projects under way, the company says it is currently expanding its facilities at Milton Park, near Oxford, UK, to cope with the increasing demand.